A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome
-
- Guillem Clot
- Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
-
- Pedro Jares
- Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
-
- Eva Giné
- Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
-
- Alba Navarro
- Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
-
- Cristina Royo
- Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
-
- Magda Pinyol
- Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
-
- David Martín-Garcia
- Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
-
- Santiago Demajo
- Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
-
- Blanca Espinet
- Pathology Department and
-
- Antonio Salar
- Hematology Department, IMIM-Hospital del Mar, Barcelona, Spain;
-
- Ana Ferrer
- Hematology Department, IMIM-Hospital del Mar, Barcelona, Spain;
-
- Ana Muntañola
- Servei d'Hematologia, Hospital Mútua de Terrassa, Terrassa, Spain;
-
- Marta Aymerich
- Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain;
-
- Hilka Rauert-Wunderlich
- Institute of Pathology, University of Würzburg, Würzburg, Germany;
-
- Elaine S. Jaffe
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;
-
- Joseph M. Connors
- Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;
-
- Randy D. Gascoyne
- Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;
-
- Jan Delabie
- Department of Pathology, Toronto General Hospital, Toronto, ON, Canada;
-
- Armando López-Guillermo
- Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
-
- German Ott
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; and
-
- George W. Wright
- Comprehensive Cancer Center Mainfranken, Würzburg, Germany;
-
- Louis M. Staudt
- Comprehensive Cancer Center Mainfranken, Würzburg, Germany;
-
- Andreas Rosenwald
- Institute of Pathology, University of Würzburg, Würzburg, Germany;
-
- David W. Scott
- Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;
-
- Lisa M. Rimsza
- Department of Pathology, Mayo Clinic, Scottsdale, AZ
-
- Sílvia Beà
- Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
-
- Elías Campo
- Institute for Biomedical Research August Pi i Sunyer, Barcelona, Spain;
Abstract
<jats:title>Key Points</jats:title> <jats:p>A new molecular assay identifies conventional and leukemic nonnodal MCL with differing clinicobiological features. The integration of the novel assay with genetic alterations identifies subsets of MCL patients with different management and outcome.</jats:p>
Journal
-
- Blood
-
Blood 132 (4), 413-422, 2018-07-26
American Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1360861712196864768
-
- ISSN
- 15280020
- 00064971
-
- Data Source
-
- Crossref